• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于炎症的预后评分对预测潜在可切除高位胆管癌高胆红素血症患者可切除性的临床价值。

Clinical Value of Inflammation-Based Prognostic Scores to Predict the Resectability of Hyperbilirubinemia Patients with Potentially Resectable Hilar Cholangiocarcinoma.

机构信息

Department of Biliary Surgery, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan Province, China.

出版信息

J Gastrointest Surg. 2019 Mar;23(3):510-517. doi: 10.1007/s11605-018-3892-9. Epub 2018 Aug 3.

DOI:10.1007/s11605-018-3892-9
PMID:30076591
Abstract

BACKGROUND

We aimed to examine whether inflammation-based prognostic scores could predict tumor resectability in a cohort of hilar cholangiocarcinoma patients with preoperative hyperbilirubinemia. We also sought to investigate the prognostic factors associated with overall survival in the subgroup of patients with an R0 resection.

METHODS

A total of 173 patients with potentially resectable hilar cholangiocarcinoma, as judged by radiological examinations, were included. The potential relationship of the Glasgow prognostic score (GPS), modified GPS, platelet lymphocyte ratio (PLR), neutrophil lymphocyte ratio (NLR), prognostic nutritional index (PNI), and prognostic index (PI) with tumor resectability were investigated using univariate and multivariate analysis.

RESULTS

Among the 173 patients, 134 had R0 resection margins. Univariate analysis identified that patients with PLR ≥ 150, NLR ≥ 3, PNI ≥ 45, GPS (0.1/2), modified GPS (0.1/2), preoperative CA 125 > 35 U/mL, and a tumor size ≥ 3 cm were more likely to have unresectable tumors. Multivariate analysis indicated that tumor size ≥ 3 cm (OR = 2.422, 95% CI: 1.053-5.573; P = 0.037), PLR ≥ 150 (OR = 3.324, 95% CI: 1.143-9.667; P = 0.027), preoperative CA 125 > 35 U/mL (OR = 3.184, 95% CI: 1.316-7.704; P = 0.010), and GPS (0.1/2) (OR = 2.440, 95% CI: 1.450-4.107; P = 0.001) were independent factors associated with tumor resectability. In selected patients with an R0 resection in this cohort, nodal status (P = 0.010) and tumor differentiation (P = 0.025) were predictive of poor survival outcome.

CONCLUSION

Patients with higher GPS, CA 125, and PLR levels, and a larger tumor size, tend to have unresectable tumors even if they were judged as potentially resectable using preoperative radiological examinations.

摘要

背景

我们旨在探讨炎症预后评分是否可预测术前高胆红素血症的肝门部胆管癌患者的肿瘤可切除性。我们还试图研究在 R0 切除亚组中与总生存相关的预后因素。

方法

共纳入 173 例经影像学检查判断为潜在可切除的肝门部胆管癌患者。采用单因素和多因素分析研究格拉斯哥预后评分(GPS)、改良 GPS、血小板淋巴细胞比值(PLR)、中性粒细胞淋巴细胞比值(NLR)、预后营养指数(PNI)和预后指数(PI)与肿瘤可切除性的潜在关系。

结果

在 173 例患者中,134 例有 R0 切缘。单因素分析发现,PLR≥150、NLR≥3、PNI≥45、GPS(0.1/2)、改良 GPS(0.1/2)、术前 CA125>35 U/mL 和肿瘤大小≥3 cm 的患者更有可能存在不可切除的肿瘤。多因素分析表明,肿瘤大小≥3 cm(OR=2.422,95%CI:1.053-5.573;P=0.037)、PLR≥150(OR=3.324,95%CI:1.143-9.667;P=0.027)、术前 CA125>35 U/mL(OR=3.184,95%CI:1.316-7.704;P=0.010)和 GPS(0.1/2)(OR=2.440,95%CI:1.450-4.107;P=0.001)是与肿瘤可切除性相关的独立因素。在本队列中选择接受 R0 切除的患者中,淋巴结状态(P=0.010)和肿瘤分化(P=0.025)是不良生存结果的预测因素。

结论

即使术前影像学检查判断为潜在可切除,GPS、CA125 和 PLR 水平较高以及肿瘤较大的患者往往存在不可切除的肿瘤。

相似文献

1
Clinical Value of Inflammation-Based Prognostic Scores to Predict the Resectability of Hyperbilirubinemia Patients with Potentially Resectable Hilar Cholangiocarcinoma.基于炎症的预后评分对预测潜在可切除高位胆管癌高胆红素血症患者可切除性的临床价值。
J Gastrointest Surg. 2019 Mar;23(3):510-517. doi: 10.1007/s11605-018-3892-9. Epub 2018 Aug 3.
2
Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma.淋巴细胞与单核细胞比值预测可切除性和毕氏Ⅳ型肝门胆管癌早期复发。
J Gastrointest Surg. 2020 Feb;24(2):330-340. doi: 10.1007/s11605-018-04086-9. Epub 2019 Jan 22.
3
Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?术前和术后CA19-9水平能否预测可切除肝门部胆管癌患者的生存及早期复发情况?
Oncotarget. 2017 Jul 11;8(28):45335-45344. doi: 10.18632/oncotarget.17336.
4
Appraisal of inflammation-based prognostic scores in patients with unresectable perihilar cholangiocarcinoma.不可切除性肝门部胆管癌患者基于炎症的预后评分评估
J Hepatobiliary Pancreat Sci. 2016 Oct;23(10):636-642. doi: 10.1002/jhbp.386. Epub 2016 Aug 30.
5
Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.术前炎症标志物对可切除胆道癌的预后价值 - 西方队列中格拉斯哥预后评分和改良格拉斯哥预后评分的验证和比较。
Eur J Surg Oncol. 2020 May;46(5):804-810. doi: 10.1016/j.ejso.2019.12.008. Epub 2019 Dec 14.
6
Predictive factors of early recurrence after R0 resection of hilar cholangiocarcinoma: A single institution experience in China.中国某单一机构 R0 切除术后肝门部胆管癌早期复发的预测因素:一项单中心经验。
Cancer Med. 2019 Apr;8(4):1567-1575. doi: 10.1002/cam4.2052. Epub 2019 Mar 13.
7
Assessment of clinical outcomes of advanced hilar cholangiocarcinoma.评估肝门部胆管癌的临床结局。
Hepatobiliary Pancreat Dis Int. 2018 Apr;17(2):155-162. doi: 10.1016/j.hbpd.2018.03.003. Epub 2018 Mar 6.
8
Surgical resection for hilar cholangiocarcinoma: experience improves resectability.肝门部胆管癌的外科切除术:经验可提高可切除性。
HPB (Oxford). 2012 Feb;14(2):142-9. doi: 10.1111/j.1477-2574.2011.00419.x. Epub 2011 Dec 12.
9
Klatskin Tumor: A Survival Analysis According to Tumor Characteristics and Inflammatory Ratios.肝门部胆管癌:基于肿瘤特征和炎症比值的生存分析。
Medicina (Kaunas). 2022 Dec 5;58(12):1788. doi: 10.3390/medicina58121788.
10
The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis.可切除性肝门部胆管癌患者预后相关的临床病理因素:一项系统评价和荟萃分析
Medicine (Baltimore). 2018 Aug;97(34):e11999. doi: 10.1097/MD.0000000000011999.

引用本文的文献

1
The prognostic role of albumin-bilirubin grade in the mortality of extrahepatic cholangiocarcinoma patients.白蛋白-胆红素分级在肝外胆管癌患者死亡率中的预后作用。
BMC Gastroenterol. 2025 May 19;25(1):383. doi: 10.1186/s12876-025-03979-9.
2
Preoperative glasgow prognostic score was an effective prognostic indicator in patients with biliary tract cancer.术前格拉斯哥预后评分是胆道癌患者有效的预后指标。
Front Immunol. 2025 Apr 8;16:1560944. doi: 10.3389/fimmu.2025.1560944. eCollection 2025.
3
Systemic Inflammatory Markers as Prognostic Factors in Oral Squamous Cell Carcinoma of the Tongue.

本文引用的文献

1
Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.根治性手术后肝门部胆管癌早期复发的定义:来自美国肝外胆管恶性肿瘤联盟的多机构研究
World J Surg. 2018 Sep;42(9):2919-2929. doi: 10.1007/s00268-018-4530-0.
2
Relationship of tumor size with pathological and prognostic factors for hilar cholangiocarcinoma.肝门部胆管癌肿瘤大小与病理及预后因素的关系
Oncotarget. 2017 Oct 23;8(62):105011-105019. doi: 10.18632/oncotarget.22054. eCollection 2017 Dec 1.
3
Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: A retrospective study at a single center.
全身炎症标志物作为舌部口腔鳞状细胞癌的预后因素
Biomedicines. 2025 Mar 20;13(3):754. doi: 10.3390/biomedicines13030754.
4
Peripheral blood biomarkers as differential diagnostic markers of disease severity in neonates with hyperbilirubinemia.外周血生物标志物作为高胆红素血症新生儿疾病严重程度的鉴别诊断标志物。
Heliyon. 2024 Dec 17;11(1):e41299. doi: 10.1016/j.heliyon.2024.e41299. eCollection 2025 Jan 15.
5
Prognostic impact of preoperative skeletal muscle change from diagnosis to surgery in patients with perihilar cholangiocarcinoma.肝门部胆管癌患者从诊断到手术期间术前骨骼肌变化的预后影响
Ann Gastroenterol Surg. 2022 Dec 11;7(3):523-532. doi: 10.1002/ags3.12644. eCollection 2023 May.
6
Klatskin Tumor: A Survival Analysis According to Tumor Characteristics and Inflammatory Ratios.肝门部胆管癌:基于肿瘤特征和炎症比值的生存分析。
Medicina (Kaunas). 2022 Dec 5;58(12):1788. doi: 10.3390/medicina58121788.
7
The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma: a systematic review and meta-analysis.中性粒细胞与淋巴细胞比值对胆管癌的预后价值:系统评价和荟萃分析。
Sci Rep. 2022 Jul 25;12(1):12691. doi: 10.1038/s41598-022-16727-w.
8
The Value of Platelet-to-Lymphocyte Ratio as a Prognostic Marker in Cholangiocarcinoma: A Systematic Review and Meta-Analysis.血小板与淋巴细胞比值作为胆管癌预后标志物的价值:一项系统评价与Meta分析
Cancers (Basel). 2022 Jan 16;14(2):438. doi: 10.3390/cancers14020438.
9
A combined prediction model for biliary tract cancer using the prognostic nutritional index and pathological findings: a single-center retrospective study.使用预后营养指数和病理结果的胆道癌联合预测模型:一项单中心回顾性研究。
BMC Gastroenterol. 2021 Oct 13;21(1):375. doi: 10.1186/s12876-021-01957-5.
10
Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of T stages in hilar cholangiocarcinoma.术前中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值作为肝门部胆管癌T分期的独立预测指标
Cancer Manag Res. 2019 Jun 4;11:5157-5162. doi: 10.2147/CMAR.S192532. eCollection 2019.
肝门部胆管癌术前胆道引流与直接手术的比较:单中心回顾性研究
Biosci Trends. 2017 Jul 24;11(3):319-325. doi: 10.5582/bst.2017.01107. Epub 2017 May 22.
4
The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer.预处理全身炎症反应是接受直肠癌新辅助治疗患者病理反应不佳的重要决定因素。
Ann Surg Oncol. 2017 May;24(5):1295-1303. doi: 10.1245/s10434-016-5684-3. Epub 2016 Nov 21.
5
Appraisal of inflammation-based prognostic scores in patients with unresectable perihilar cholangiocarcinoma.不可切除性肝门部胆管癌患者基于炎症的预后评分评估
J Hepatobiliary Pancreat Sci. 2016 Oct;23(10):636-642. doi: 10.1002/jhbp.386. Epub 2016 Aug 30.
6
Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma.术前血清CA 19-9和CA 125水平预测肝门部胆管癌可切除性的临床价值
Springerplus. 2016 Apr 30;5:551. doi: 10.1186/s40064-016-2181-x. eCollection 2016.
7
Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China.肝门部胆管癌的预后因素及长期结局:中国单中心经验
World J Gastroenterol. 2016 Feb 28;22(8):2601-10. doi: 10.3748/wjg.v22.i8.2601.
8
The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC).CA125/MUC16在胰腺癌中的临床应用:中国胰腺癌研究组(CSPAC)关于诊断、预后及预测更新的共识
Int J Oncol. 2016 Mar;48(3):900-7. doi: 10.3892/ijo.2015.3316. Epub 2015 Dec 30.
9
Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma.改良格拉斯哥预后评分在肝细胞癌根治性手术患者中的预后价值
Medicine (Baltimore). 2015 Sep;94(36):e1486. doi: 10.1097/MD.0000000000001486.
10
Evaluation of inflammation-based prognostic scores in patients undergoing hepatobiliary resection for perihilar cholangiocarcinoma.肝门部胆管癌患者行肝胆切除术后基于炎症的预后评分评估
J Gastroenterol. 2016 Feb;51(2):153-61. doi: 10.1007/s00535-015-1103-y. Epub 2015 Jul 18.